Swine Vaccines Market to Grow with a CAGR of 4.85% through 2028
Rising demand for pork, the imperative need for
disease prevention, and advancements in vaccine technology are expected to
drive the Global Swine Vaccines Market growth in the forecast period,
2024-2028.
According to TechSci Research report, “Swine
Vaccines Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Swine Vaccines Market stood
at USD 1.32 billion in 2022 and is anticipated to grow with a CAGR of 4.85% in
the forecast period, 2024-2028. This can be attributed to adoption of
biosecurity measures. Farmers are increasingly recognizing the importance of
biosecurity measures in swine farming. Alongside vaccination, biosecurity
practices such as controlled access to farms, quarantine protocols, and
sanitation help prevent the introduction and spread of diseases. The combined
use of vaccines and biosecurity measures enhances disease control and supports
market growth.
Furthermore, consumer preferences are driving changes
in the swine industry, including vaccine usage. Consumers increasingly demand
higher standards of animal welfare, antibiotic-free products, and
environmentally sustainable practices. Swine vaccines play a role in meeting
these demands by supporting healthier herds and reducing the need for
antibiotics.
As a result of a rising number of swine disease
outbreaks reported in major swine-raising nations, there is a growing demand
from customers for innovative, rapid, safe, and effective vaccines. For
instance, according to the OIE (World Organisation for Animal Health), between
2016 and 2020, Asian swine herds reported a total of 9,928 outbreaks of African
swine fever, followed by 4,721 outbreaks in Europe. To address this severe
swine health concern, government agencies and pharmaceutical companies are continuously
introducing new vaccines. For instance, in June 2022, Vietnam announced the
successful development of an ASF (African swine fever) vaccine intended for
distribution across the country's swine farms. However, the vaccine's use was
temporarily halted in August 2022 due to concerns about mortality rates among
vaccinated swine.
The COVID-19 pandemic disrupted the distribution of
critically needed swine vaccines in the early months of 2020, resulting in
significant losses for swine producers and vaccine manufacturers. This
disruption was primarily due to global lockdowns and supply chain restrictions
implemented to contain the spread of COVID-19. Governments and healthcare
sectors were primarily focused on managing human emergency treatments during
the crisis while also grappling with the increasing incidence of contagious
swine diseases affecting the overall livestock industry. Various measures,
including import and export bans, strengthened biosecurity protocols, routine
surveillance, epidemiological investigations, and vaccination campaigns, were
implemented in different regions to curb the spread of these diseases.
Furthermore, companies in the market are introducing a
range of innovative vaccine technologies and solutions, which are contributing
to market growth. For example, in October 2019, Boehringer Ingelheim received
authorization from the European Medicines Agency (EMA) for ReprocycParvoFLEX,
the first subunit porcine parvovirus vaccine designed to protect swine fetuses
against transplacental infection. Additionally, veterinary universities are
actively providing vaccination services to assist small-scale swine farmers in
implementing disease control measures. For instance, the College of Veterinary
Medicine at the University of Illinois established a website to offer
information and resources to pork producers for enhancing their on-farm
biosecurity programs. Training farm employees and developing biosecurity plans
are crucial steps in preventing the entry and spread of high-risk pathogens in
swine farms, further contributing to market growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Swine Vaccines Market.”
The Global Swine Vaccines Market is segmented into
product, type, target disease, regional distribution, and company.
Based on its product, the category of inactivated
vaccines held a dominant position in the market and contributed the most
substantial portion of revenue in 2022. This can be attributed to several
factors, including their easy accessibility, cost-effectiveness, and stability
advantages when compared to live-attenuated vaccines. Inactivated vaccines are
effective in minimizing the risk of pathogens regaining virulence after
vaccination since they halt the replication process of these harmful agents.
Additionally, they offer swine enhanced immunization with a swift cell-mediated
immune response. The immunity achieved through inactivated vaccines can be
further bolstered by the inclusion of adjuvants like specific types of oils or
aluminum hydroxide. However, it is crucial to exercise significant caution when
preparing, storing, and handling inactivated vaccines to ensure their efficacy.
On the other hand, the segment dedicated to
recombinant vaccines is projected to experience the most rapid growth rate
during the forecast period. These vaccines are expected to play a pivotal role
in achieving immunization against a wide array of virus strains, as they have
the capability to carry multiple gene inserts. An example of such a swine
recombinant vaccine is IngelvacCircoFLEX, developed by Boehringer Ingelheim
International GmbH, which offers active immunization for pigs aged two weeks
and older. Formulated vaccines of this nature can enhance stability, viability,
and eliminate the need for adjuvants. Some of the available recombinant
vaccines for swine target diseases such as pseudorabies, porcine circovirus
type 2, and classical swine fever (CSF).
Based on region, Asia Pacific secured the largest
portion of revenue in 2022, and it is projected to experience the most rapid
CAGR during the forecast period. Several key factors contribute to this
substantial market share. Notably, the region is home to major swine-producing
nations, with China at the forefront. Additionally, the Asia Pacific region
boasts a sizable population with a strong appetite for meat, driving a
significant demand for vaccines to combat the increasing incidence of diseases
among Asian swine herds. Furthermore, Asia had the highest pig population in
2021, numbering 462.6 million pigs, with China leading the pack with
approximately 347 million pigs. Moreover, China's pork consumption reached
43,843 thousand tonnes in 2021.
In other regions such as Latin America, North America,
and Europe, the swine vaccines market is also expected to witness substantial
growth in the coming years. This growth can be attributed to the increasing
swine population and the widespread adoption of biosecurity measures, including
routine vaccination. North America, in particular, held a significant share of
revenue in 2022. This is due to the region's well-established veterinary
healthcare infrastructure, a growing demand for animal protein, highly organized
farming practices, and an increased investment in animal health. Countries like
the United States and Canada benefit from robust and well-defined healthcare
systems and a concentration of key industry players.
Major companies operating in Global Swine
Vaccines Market are:
- Merck & Co Inc
- Zoetis Inc
- Boehringer Ingelheim GmbH
- Elanco Animal Health Inc
- Indian Immunologicals Ltd
- Biogénesis Bagó
- Phibro Animal Health Corp
- Laboratorios HIPRA SA
- Virbac SA
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global swine vaccines market is evolving to meet
the complex challenges of disease prevention in a dynamic swine farming
industry. Emerging trends such as precision vaccination, next-generation
vaccine platforms, data-driven decisions, and enhanced biosecurity measures are
shaping the future of swine vaccination. These developments not only contribute
to healthier swine herds but also align with the demands of consumers for safe,
high-quality, and sustainable pork products. As the swine industry continues to
grow and adapt, staying attuned to these trends will be essential for success
in the global swine vaccines market,” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Swine Vaccines Market By
Product (Attenuated Live Vaccines, DNA Vaccines,
Inactivated Vaccines, Recombinant Vaccines, Subunit Vaccines), By Type
(Actinobacillus Pleuropneumoniae, Classical Swine Fever, Foot & Mouth
Disease, PEDV, Porcine Circovirus Type 2, Porcine Parvovirus, PRRS,
Pseudorabies, Swine Influenza), By Target Disease (Arthritis, Bordetella
Rhinitis, Diarrhea, Foot & Mouth Disease, Porcine Circovirus Associated
Disease, Porcine Reproductive & Respiratory Syndrome, Pseudorabies, Swine
Influenza), By
Region, By Competition Forecast
& Opportunities, 2018-2028F”, has evaluated the future growth potential of Global
Swine Vaccines Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Swine Vaccines Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com